{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:53:09Z","timestamp":1769550789475,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,27]]},"DOI":"10.7759\/cureus.102365","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T08:21:10Z","timestamp":1769502070000},"source":"Crossref","is-referenced-by-count":0,"title":["The Effect of Bevacizumab Therapy on Reducing Erythrocyte Transfusion Requirements and Preventing Iron Deficiency in Patients With Hereditary Hemorrhagic Telangiectasia"],"prefix":"10.7759","author":[{"given":"\u00d6znur","family":"Ayd\u0131n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fato\u015f Dilan","family":"K\u00f6seo\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selim","family":"Say\u0131n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilmi Erdem","family":"G\u00f6zden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onur","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00dcnal","family":"Ata\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derya Deniz","family":"K\u00fcrekci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sude Hatun","family":"Aktimur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meltem","family":"Ayl\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Turgut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serkan","family":"G\u00fcven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-017-0586-z","article-title":"Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT)","volume":"15","author":"Zarrabeitia R","year":"2017","unstructured":"Zarrabeitia R, Fari\u00f1as-\u00c1lvarez C, Santib\u00e1\u00f1ez M, Se\u00f1aris B, Fontalba A, Botella LM, Parra JA. Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT). Health Qual Life Outcomes. 2017, 15:19. 10.1186\/s12955-017-0586-z","journal-title":"Health Qual Life Outcomes"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X18767761","article-title":"Life expectancy and comorbidities in patients with hereditary hemorrhagic telangiectasia","volume":"23","author":"Droege F","year":"2018","unstructured":"Droege F, Thangavelu K, Stuck BA, Stang A, Lang S, Geisthoff U. Life expectancy and comorbidities in patients with hereditary hemorrhagic telangiectasia. Vasc Med. 2018, 23:377-83. 10.1177\/1358863X18767761","journal-title":"Vasc Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-017-4719-3","article-title":"Gastrointestinal manifestations of hereditary hemorrhagic telangiectasia (HHT): a systematic review of the literature","volume":"62","author":"Jackson SB","year":"2017","unstructured":"Jackson SB, Villano NP, Benhammou JN, Lewis M, Pisegna JR, Padua D. Gastrointestinal manifestations of hereditary hemorrhagic telangiectasia (HHT): a systematic review of the literature. Dig Dis Sci. 2017, 62:2623-30. 10.1007\/s10620-017-4719-3","journal-title":"Dig Dis Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2009.35","article-title":"Hereditary haemorrhagic telangiectasia: a clinical and scientific review","volume":"17","author":"Govani FS","year":"2009","unstructured":"Govani FS, Shovlin CL. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet. 2009, 17:860-71. 10.1038\/ejhg.2009.35","journal-title":"Eur J Hum Genet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X231151731","article-title":"Multidisciplinary coordinated care of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease)","volume":"28","author":"Alkhalid Y","year":"2023","unstructured":"Alkhalid Y, Darji Z, Shenkar R, Clancy M, Dyamenahalli U, Awad IA. Multidisciplinary coordinated care of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease). Vasc Med. 2023, 28:153-65. 10.1177\/1358863X231151731","journal-title":"Vasc Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2015.00001","article-title":"Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era","volume":"6","author":"McDonald J","year":"2015","unstructured":"McDonald J, Wooderchak-Donahue W, VanSant Webb C, Whitehead K, Stevenson DA, Bayrak-Toydemir P. Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. Front Genet. 2015, 6:1. 10.3389\/fgene.2015.00001","journal-title":"Front Genet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2010.07.001","article-title":"Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment","volume":"24","author":"Shovlin CL","year":"2010","unstructured":"Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev. 2010, 24:203-19. 10.1016\/j.blre.2010.07.001","journal-title":"Blood Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/pediatric15010011","article-title":"Hereditary hemorrhagic telangiectasia in pediatric age: focus on genetics and diagnosis","volume":"15","author":"Danesino C","year":"2023","unstructured":"Danesino C, Cantarini C, Olivieri C. Hereditary hemorrhagic telangiectasia in pediatric age: focus on genetics and diagnosis. Pediatr Rep. 2023, 15:129-42. 10.3390\/pediatric15010011","journal-title":"Pediatr Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-8628(20000306)91:1<66::aid-ajmg12>3.0.co;2-p","article-title":"Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)","volume":"91","author":"Shovlin CL","year":"2000","unstructured":"Shovlin CL, Guttmacher AE, Buscarini E, et al.. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000, 91:66-7. 10.1002\/(sici)1096-8628(20000306)91:1&lt;66::aid-ajmg12&gt;3.0.co;2-p","journal-title":"Am J Med Genet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092634","article-title":"Hereditary hemorrhagic telangiectasia and arterio-venous malformations: from diagnosis to therapeutic challenges","volume":"11","author":"Floria M","year":"2022","unstructured":"Floria M, N\u0103fureanu ED, Iov DE, et al.. Hereditary hemorrhagic telangiectasia and arterio-venous malformations: from diagnosis to therapeutic challenges. J Clin Med. 2022, 11:2634. 10.3390\/jcm11092634","journal-title":"J Clin Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.193003","article-title":"Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective","volume":"103","author":"Kritharis A","year":"2018","unstructured":"Kritharis A, Al-Samkari H, Kuter DJ. Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective. Haematologica. 2018, 103:1433-43. 10.3324\/haematol.2018.193003","journal-title":"Haematologica"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1443","article-title":"Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia","volume":"173","author":"Faughnan ME","year":"2020","unstructured":"Faughnan ME, Mager JJ, Hetts SW, et al.. Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. Ann Intern Med. 2020, 173:989-1001. 10.7326\/M20-1443","journal-title":"Ann Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008739","article-title":"Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care","volume":"137","author":"Al-Samkari H","year":"2021","unstructured":"Al-Samkari H. Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care. Blood. 2021, 137:888-95. 10.1182\/blood.2020008739","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2022.104575","article-title":"European Reference Network for Rare Vascular Diseases (VASCERN): when and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?","volume":"65","author":"Dupuis-Girod S","year":"2022","unstructured":"Dupuis-Girod S, Shovlin CL, Kjeldsen AD, et al.. European Reference Network for Rare Vascular Diseases (VASCERN): when and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?. Eur J Med Genet. 2022, 65:104575. 10.1016\/j.ejmg.2022.104575","journal-title":"Eur J Med Genet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1281-4","article-title":"Future treatments for hereditary hemorrhagic telangiectasia","volume":"15","author":"Robert F","year":"2020","unstructured":"Robert F, Desroches-Castan A, Bailly S, Dupuis-Girod S, Feige JJ. Future treatments for hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2020, 15:4. 10.1186\/s13023-019-1281-4","journal-title":"Orphanet J Rare Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.261859","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study","volume":"106","author":"Al-Samkari H","year":"2021","unstructured":"Al-Samkari H, Kasthuri RS, Parambil JG, et al.. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. Haematologica. 2021, 106:2161-9. 10.3324\/haematol.2020.261859","journal-title":"Haematologica"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13714","article-title":"Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: a national, randomized multicenter trial","volume":"294","author":"Dupuis-Girod S","year":"2023","unstructured":"Dupuis-Girod S, Rivi\u00e8re S, Lavigne C, et al.. Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: a national, randomized multicenter trial. J Intern Med. 2023, 294:761-74. 10.1111\/joim.13714","journal-title":"J Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2017-001293","article-title":"Intranasal bevacizumab treatment on epistaxis in hereditary haemorrhagic telangiectasia: a case report","volume":"26","author":"Garc\u00eda-Mart\u00edn E","year":"2019","unstructured":"Garc\u00eda-Mart\u00edn E, Pern\u00eda-L\u00f3pez S, Mart\u00ednez-Ortega PA, Monje B, Ruiz-Mart\u00ednez C, Sanjurjo-Saez M. Intranasal bevacizumab treatment on epistaxis in hereditary haemorrhagic telangiectasia: a case report. Eur J Hosp Pharm. 2019, 26:226-8. 10.1136\/ejhpharm-2017-001293","journal-title":"Eur J Hosp Pharm"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/hed.23655","article-title":"Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial","volume":"37","author":"Riss D","year":"2015","unstructured":"Riss D, Burian M, Wolf A, Kranebitter V, Kaider A, Arnoldner C. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial. Head Neck. 2015, 37:783-7. 10.1002\/hed.23655","journal-title":"Head Neck"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.11724","article-title":"Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial","volume":"316","author":"Whitehead KJ","year":"2016","unstructured":"Whitehead KJ, Sautter NB, McWilliams JP, et al.. Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial. JAMA. 2016, 316:943-51. 10.1001\/jama.2016.11724","journal-title":"JAMA"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00195-7","article-title":"Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study","volume":"2","author":"Invernizzi R","year":"2015","unstructured":"Invernizzi R, Quaglia F, Klersy C, et al.. Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study. Lancet Haematol. 2015, 2:e465-73. 10.1016\/S2352-3026(15)00195-7","journal-title":"Lancet Haematol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312749","article-title":"Pomalidomide for epistaxis in hereditary hemorrhagic telangiectasia","volume":"391","author":"Al-Samkari H","year":"2024","unstructured":"Al-Samkari H, Kasthuri RS, Iyer VN, et al.. Pomalidomide for epistaxis in hereditary hemorrhagic telangiectasia. N Engl J Med. 2024, 391:1015-27. 10.1056\/NEJMoa2312749","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11185280","article-title":"Efficacy and safety of tacrolimus as treatment for bleeding caused by hereditary hemorrhagic telangiectasia: an open-label pilot study","volume":"11","author":"Hessels J","year":"2022","unstructured":"Hessels J, Kroon S, Boerman S, et al.. Efficacy and safety of tacrolimus as treatment for bleeding caused by hereditary hemorrhagic telangiectasia: an open-label pilot study. J Clin Med. 2022, 11:5280. 10.3390\/jcm11185280","journal-title":"J Clin Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI127425","article-title":"Correcting Smad1\/5\/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models","volume":"130","author":"Ruiz S","year":"2020","unstructured":"Ruiz S, Zhao H, Chandakkar P, et al.. Correcting Smad1\/5\/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models. J Clin Invest. 2020, 130:942-57. 10.1172\/JCI127425","journal-title":"J Clin Invest"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27756","article-title":"Characterizing the healthcare utilization and costs of hereditary hemorrhagic telangiectasia","volume":"100","author":"Al-Samkari H","year":"2025","unstructured":"Al-Samkari H, Mayne TJ, Troutt M, Patle H, Clancy M, Duhaime E. Characterizing the healthcare utilization and costs of hereditary hemorrhagic telangiectasia. Am J Hematol. 2025, 100:1722-35. 10.1002\/ajh.27756","journal-title":"Am J Hematol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12832","article-title":"Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia","volume":"285","author":"Al-Samkari H","year":"2019","unstructured":"Al-Samkari H, Kritharis A, Rodriguez-Lopez JM, Kuter DJ. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. J Intern Med. 2019, 285:223-31. 10.1111\/joim.12832","journal-title":"J Intern Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.11.013","article-title":"Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding","volume":"93","author":"Iyer VN","year":"2018","unstructured":"Iyer VN, Apala DR, Pannu BS, et al.. Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding. Mayo Clin Proc. 2018, 93:155-66. 10.1016\/j.mayocp.2017.11.013","journal-title":"Mayo Clin Proc"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1089847","article-title":"Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis","volume":"14","author":"Chen H","year":"2023","unstructured":"Chen H, Zhang Z, Chen X, et al.. Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis. Front Pharmacol. 2023, 14:1089847. 10.3389\/fphar.2023.1089847","journal-title":"Front Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/20406207241300828","article-title":"BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study","volume":"16","author":"Dupuis-Girod S","year":"2025","unstructured":"Dupuis-Girod S, Decullier E, Rivi\u00e8re S, et al.. BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study. Ther Adv Hematol. 2025, 16:10.1177\/20406207241300828","journal-title":"Ther Adv Hematol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012589","article-title":"Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia","volume":"8","author":"Wang D","year":"2024","unstructured":"Wang D, Ito S, Waldron C, et al.. Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia. Blood Adv. 2024, 8:2835-45. 10.1182\/bloodadvances.2024012589","journal-title":"Blood Adv"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/455860-the-effect-of-bevacizumab-therapy-on-reducing-erythrocyte-transfusion-requirements-and-preventing-iron-deficiency-in-patients-with-hereditary-hemorrhagic-telangiectasia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T08:21:11Z","timestamp":1769502071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/455860-the-effect-of-bevacizumab-therapy-on-reducing-erythrocyte-transfusion-requirements-and-preventing-iron-deficiency-in-patients-with-hereditary-hemorrhagic-telangiectasia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.102365","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,27]]}}}